Cardiol Therapeutics Inc-a (CRDL) — 13F Holders Deep Dive (Q2 2026)

CRDL ranks #5973 out of 37701 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

CRDL is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

54 institutions disclose a position in CRDL, but none treat it as a major bet — even Tejara Capital Ltd, its most concentrated holder, allocates just 2.2% of its own portfolio to it.

Pvg Asset Management CORP has added to its CRDL position for two straight quarters, increasing it by $73.2K to reach $185.7K today.

CRDL is up 1.7% today, and institutions have been net buyers of $1.8M this quarter — today's price move and the underlying institutional flow are pointing the same direction.

CRDL reported a net loss of $28.1M in its latest fiscal year.

• Not yet profitable — net loss of $28.1M in the latest fiscal year
• Net income improved year over year, from -$30.9M to -$28.1M
• Operating cash flow was negative, using $25.2M in cash
• Current ratio of 4.36x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.30x equity — within a conventional range